A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma

D. Errante, R. Sorio, V. Zagonel, A. Carbone, S. Monfardini, U. Tirelli

Research output: Contribution to journalArticlepeer-review

Abstract

Eighteen untreated elderly patients (median age 75 years) with non-Hodgkin's lymphoma (NHL) entered a phase II study with oral Idarubicin (4-demethoxidaunorubicin) at a dosage of 30-35 mg/m2 on day 1 and every 3 weeks thereafter. The median number of cycles administered was three (range one to nine). We obtained one (6%) complete response and four (25%) partial responses in 16 evaluable patients. Toxicity was mild and no cardiotoxicity was found. At this dosage Idarubicin showed little anticancer activity in NHL.

Original languageEnglish
Pages (from-to)243-245
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number3
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this